Physician profile
Elsayed M Aly
NPI 1154313260
$8,536.88
in general payments reported to CMS, 2019-2025
53 companies · $1,981 in 2025
The $1,981 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $639 · 2020: $168 · 2021: $195 · 2022: $1,513 · 2023: $1,851 · 2024: $2,190 · 2025: $1,981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,470 · Education: $552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,469.87 |
| Education | $552.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,170.85 | 2019-2025 | Kisqali, Piqray |
| Pfizer INC. | $837.22 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $670.33 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Seagen INC. | $637.16 | 2019-2024 | Padcev |
| Astellas Pharma US INC | $558.16 | 2022-2025 | Xospata, Padcev, Xtandi |
| Gilead Sciences, INC. | $529.91 | 2019-2025 | Trodelvy |
| Janssen Biotech, INC. | $418.69 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Amgen INC. | $340.27 | 2019-2023 | Lumakras |
| Genzyme Corporation | $329.29 | 2019-2025 | |
| Abbvie INC. | $261.42 | 2022-2025 | Venclexta |
| Servier Pharmaceuticals LLC | $221.03 | 2022-2025 | |
| Daiichi Sankyo INC. | $220.92 | 2022-2025 | Enhertu, Datroway |
| Celgene Corporation | $201.28 | 2021-2025 | Reblozyl |
| Astrazeneca Pharmaceuticals Lp | $195.88 | 2022-2025 | Lynparza, Enhertu, Airsupra |
| E.R. Squibb & Sons, L.L.C. | $150.81 | 2019-2024 | Opdivo |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $140.99 | 2019-2023 | Rozlytrek, Alecensa, Gavreto |
| Pharmacosmos Therapeutics INC. | $123.34 | 2022-2025 | Monoferric |
| Sobi, INC | $114.14 | 2023-2024 | |
| Acrotech Biopharma INC. | $98.26 | 2022-2025 | Beleodaq |
| Eisai INC. | $93.48 | 2019-2023 | |
| Kite Pharma, INC. | $88.12 | 2022-2025 | Yescarta |
| Glaxosmithkline, LLC. | $86.75 | 2023-2025 | Zejula, Ojjaara, Blenrep |
| Array Biopharma INC | $86.33 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.34 | 2020-2025 | |
| Jazz Pharmaceuticals INC. | $81.18 | 2023-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $76.36 | 2020-2022 | |
| Mirati Therapeutics, INC. | $56.16 | 2023 | Krazati |
| Adc Therapeutics America, INC. | $54.53 | 2022-2023 | |
| Sun Pharmaceutical Industries INC. | $45.24 | 2023-2025 | Yonsa, Odomzo |
| Ipsen Biopharmaceuticals, INC | $43.45 | 2025 | Onivyde, Somatuline Depot |
| Lilly USA, LLC | $38.82 | 2023-2024 | Jaypirca, Verzenio |
| Takeda Pharmaceuticals U.S.A., INC. | $38.63 | 2021-2024 | Fruzaqla |
| Foundation Medicine, INC. | $38.00 | 2022-2023 | Foundationone Cdx |
| Pharmaessentia USA Corporation | $37.78 | 2023 | Besremi |
| Beone Medicines USA, INC. | $36.22 | 2025 | Brukinsa |
| Alexion Pharmaceuticals, INC. | $35.71 | 2023-2025 | Ultomiris |
| Genmab U.S., INC. | $34.75 | 2023-2024 | Epkinly |
| Adaptive Biotechnologies Corporation | $24.04 | 2024 | Clonoseq |
| Cti Biopharma Corp. | $23.45 | 2023 | Vonjo |
| Incyte Corporation | $20.47 | 2024 | Jakafi |
| Myriad Genetic Laboratories, INC. | $19.09 | 2022 | |
| Emd Serono, INC. | $18.87 | 2023 | Bavencio |
| Cumberland Pharmaceuticals, INC. | $18.44 | 2025 | Sancuso |
| Recordati_rare_diseases_inc. | $17.50 | 2025 | Sylvant |
| Taiho Oncology, INC. | $17.49 | 2023 | |
| Legend Biotech USA INC. | $17.38 | 2025 | Carvykti |
| Exelixis INC. | $16.62 | 2023 | Cabometyx |
| Morphosys, US INC. | $15.82 | 2023 | Monjuvi |
| Dova Pharmaceuticals | $13.48 | 2019 | |
| Tempus Ai, INC | $13.25 | 2024 | |
| Helsinn Therapeutics (U.S.), INC. | $12.51 | 2019 | |
| Janssen Scientific Affairs, LLC | $10.70 | 2025 | Rybrevant |
| Clovis Oncology, INC. | $4.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elsayed Aly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.